Surgimab SAS is focused on developing innovative therapeutic solutions, particularly in the field of immunotherapy. The company specializes in the creation of monoclonal antibodies that target specific antigens associated with various diseases, including cancer. Their proprietary technology platform enables the design and production of highly specific and effective antibodies, which are engineered to enhance the immune response against tumor cells. This approach aims to improve patient outcomes by harnessing the body's own immune system to fight malignancies more effectively.

In addition to their monoclonal antibody development, Surgimab SAS is also exploring advanced delivery systems to optimize the therapeutic efficacy of their products. This includes the use of novel formulations that enhance the stability and bioavailability of their antibodies, ensuring that they reach their intended targets within the body. The company is committed to advancing its pipeline through rigorous scientific research and clinical trials, with the goal of bringing transformative therapies to patients suffering from serious health conditions.

France

Surgimab SAS is a biotechnology company based out of Montpellier, Languedoc-Roussillon, France.

Surgimab SAS

Company Details